Zoryl MP 1 Tablet ER is a combination oral antidiabetic medication containing Glimepiride 1mg, Metformin 500mg, and Pioglitazone 15mg, formulated for extended release to optimize glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to increase insulin secretion, thereby lowering blood glucose levels. Metformin, a biguanide, primarily acts by reducing hepatic glucose production and improving peripheral insulin sensitivity, contributing to enhanced glucose uptake in muscle tissues. Pioglitazone, a thiazolidinedione, further improves insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), which modulates glucose and lipid metabolism. The combined action of these agents addresses multiple pathophysiological defects in type 2 diabetes, facilitating better glycemic control. Zoryl MP 1 Tablet ER is indicated as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on monotherapy or dual therapy. The extended-release formulation allows for once-daily dosing, improving patient adherence. Caution is advised in patients with hepatic or renal impairment, heart failure, or a history of lactic acidosis. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy to ensure safety and efficacy.